The coronavirus outbreak in almost all countries in the world, termed as COVID-19, and its fast spread, have endangered millions of lives. This pandemic has catalyzed the development of vaccines and drugs for COVID-19 across the biotech industry, including both pharmaceutical companies and research organizations. —
Developing a new drug is incredibly hard, which requires much effort and time. Thus, despite great efforts from the industry, a viable drug treatment is still under development. Creative Biolabs has spared no efforts to enhance the professions in the drug discovery and development process by updating RNA polymerase inhibitors development services for the treatment of SARS-CoV-2, and have more hope for speeding up this process than ever before—and not just to defeat SARS-CoV-2, but to benefit the development of all new medicines in the future.
· siRNA for the Treatment of SARS-CoV-2
Previous studies provide evidence that siRNA has an antiviral effect against various viruses, including SARS-CoV. Based on the successful experience of SARS-CoV, the expert team at Creative Biolabs has designed a series of siRNAs targeting different sites of the SARS-CoV-2, which were appropriate in length and had a G/C content of 30-50%. Other types of characterization of the siRNA are also available, covering effect, biophysical characters and cellular activities.
· Guanosine Analogue for the Treatment of SARS-CoV-2
Some guanosine analogues have been already widely used, such as acyclovir, penciclovir and ganciclovir. And for SARS-CoV-2 treatment, Creative Biolabs has been focusing on developing different series of flexible guanosine analogue, and it has optimized characterization of the compound for studying the effect, biophysical characters and cellular activities.
· Adenosine Analogue for the Treatment of SARS-CoV-2
Studies indicated that adenosine analogues revealed high efficacy as RNA polymerase inhibitors. For example, at the beginning of the COVID-19 outbreak, scientists had studied remdesivir against SARS-CoV-2 since it is recognized as a promising antiviral drug against a wide array of RNA viruses (including SARS and MERS-CoV) infection.
Creative Biolabs offers custom drug discovery services including synthesis of reference adenosine analogues or new-designed adenosine analogues, CreDA™ developability assessment, biophysical characterization and modeling, molecular engineering, and in vitro pharmacodynamics.
In addition, the inhibitor discovery services cover a wide range of antiviral agents, such as nucleoside analogue inhibitors, viral protease inhibitors, neuraminidase inhibitors, and host cell protease inhibitors for SARS-CoV-2 treatment.
More information about coronavirus-related vaccine and drug discovery services, IVD immunoassays as well as a wide range of products can be found on https://sars-cov-2.creative-biolabs.com/.
About Creative Biolabs
Empowered by leading technology and over 15 years of experience in biomedical science, Creative Biolabs has successfully accomplished numerous challenging projects for customers in requirements with accumulated experience in drug discovery and vaccine development. Especially in the field of antiviral drugs and vaccines, Creative Biolabs provides drug discovery, vaccine design, preclinical evaluation of drugs and vaccines, and in vitro diagnostic services at the world-leading level.
Release ID: 89002387